2020年11月17日 · Therefore, this study suggests the GSK-LSD1 as a therapeutic agent for severe COVID-19 patients that are difficult to treat by directly targeting NF-κB. COVID-19 patients with ARDS and sepsis (severe COVID-19) displayed the uncontrolled NF-κB p65-related cytokine release syndrome (CRS).

2020年11月17日 · Here, we applied a mechanism by which previously reported phosphorylated lysine-specific demethylase 1 (LSD1) stabilizes NF-κB p65 to control the expression of pro-inflammatory cytokine genes. 3...

GSK-LSD1 dihydrochloride is a potent, selective and irreversible lysine specific demethylase 1 (LSD1) inhibitor with an IC 50 of 16 nM.

Gsk-lsd1 | C14H20N2 | CID 71522234 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.

2020年11月17日 · GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro Signal Transduct Target Ther . 2020 Nov 17;5(1):267. doi: …

Lysine specific demethylase 1 (LSD1) is a histone demethylase found in various transcriptional co-repressor complexes. LSD1 is involved in ES cell differentiation, hematopoiesis, and has been described as having a role in Acute Myeloid Leukemia (AML).

GSK-LSD1 is a potent and selective inhibitor of lysine specific demethylase 1 (LSD1). GSK-LSD1 potently inhibits proliferation of varies cancer cell lines by changing gene expression patterns. For full characterization details, please visit the GSK-LSD1 probe summary on the Structural Genomics Consortium (SGC) website.

GSK LSD 1 dihydrochloride is a potent and selective lysine specific demethylase 1 (LSD1) inhibitor (IC 50 = 16 nM). Exhibits >1000-fold selectivity for LSD1 over closely related enzymes including LSD2, MAO-1 and MAO-B. Inhibits cancer cell line growth in vitro .

GSK-LSD1 reduces food intake and body weight, and improves insulin sensitivity and glycemic control in mouse models of obesity. GSK-LSD1 also ameliorates NAFLD. GSK-LSD1 inhibits SARS-CoV-2-triggered cytokine release in COVID-19 PBMCs.